Arrowhead Pharmaceuticals Inc ARWR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
22.91UNCH (UNCH)
Volume
287,006
Close
22.91quote price arrow up+0.85 (+3.85%)
Volume
1,758,774
52 week range
20.67 - 40.89
Loading...
  • Open22.39
  • Day High24.22
  • Day Low22.39
  • Prev Close22.06
  • 52 Week High40.89
  • 52 Week High Date05/15/23
  • 52 Week Low20.67
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap2.838B
  • Shares Out123.90M
  • 10 Day Average Volume1.09M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-25.13

KEY STATS

  • Open22.39
  • Day High24.22
  • Day Low22.39
  • Prev Close22.06
  • 52 Week High40.89
  • 52 Week High Date05/15/23
  • 52 Week Low20.67
  • 52 Week Low Date12/01/23
  • Market Cap2.838B
  • Shares Out123.90M
  • 10 Day Average Volume1.09M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-25.13

RATIOS/PROFITABILITY

  • EPS (TTM)-4.24
  • P/E (TTM)-5.41
  • Fwd P/E (NTM)-10.19
  • EBITDA (TTM)-457.822M
  • ROE (TTM)-101.18%
  • Revenue (TTM)35.473M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,346.13%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arrowhead Pharmaceuticals Inc

 

Profile

MORE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting...
Douglass Given M.D., Ph.D.
Independent Chairman of the Board
Christopher Anzalone Ph.D.
President, Chief Executive Officer, Director
Patrick O'Brien J.D.
Chief Operating Officer, General Counsel, Company Secretary
Kenneth Myszkowski
Chief Financial Officer
Address
177 E Colorado Blvd, Suite 700
Pasadena, CA
91105
United States

Top Peers

SYMBOLLASTCHG%CHG
MRUS
Merus NV
44.77-1.08-2.36%
CLDX
Celldex Therapeutics Inc
39.47-0.64-1.60%
MLTX
MoonLake Immunotherapeutics
40.77-0.94-2.25%
JANX
Janux Therapeutics Inc
47.91-2.08-4.16%
RNA
Avidity Biosciences Inc
28.91+2.89+11.11%